News stories on health policy developments from the Hill and their effect on the pharmaceutical industry
October 1, 2009
By:Jill Wechsler
All the focus on drug safety raises concerns about FDA delays in approving new drugs for market.
 |
September 1, 2009
By:Jill Wechsler
Pharma steps up development of new vaccines and treatments to combat Third World diseases
|
August 1, 2009
By:Jill Wechsler
Pressure to expand healthcare puts drug pricing, marketing, and innovation on the negotiating table.
|
July 1, 2009
By:Jill Wechsler
As FDA looks to balance risks and benefits, more regulations are on the horizon.
|
June 1, 2009
By:Jill Wechsler
FDA is seeking more resources to support compliance and oversight.
|
May 1, 2009
By:Jill Wechsler
Pharma fears comparative effectiveness research will focus on costs and stymie personalized medicine.
|
April 1, 2009
By:Jill Wechsler
In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
|
March 1, 2009
By:Jill Wechsler
The latest buzzword in pharma is "transparency"
|
February 1, 2009
By:Jill Wechsler
A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings Tuesday, December 15 @ 11:00 a.m. ET
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?